



US009185890B2

(12) **United States Patent**
Porter et al.

(10) **Patent No.:** **US 9,185,890 B2**
(45) **Date of Patent:** **Nov. 17, 2015**

(54) **MMTV-SV40-SPY1A AND SPY1A-PTRE
TRANSGENIC MOUSE MODELS**

(71) Applicants: **Lisa Porter**, Windsor (CA); **Bre-Anne
Fifield**, Windsor (CA); **Dorota
Lubanska**, Windsor (CA); **Espanta
Jalili**, Windsor (CA)

(72) Inventors: **Lisa Porter**, Windsor (CA); **Bre-Anne
Fifield**, Windsor (CA); **Dorota
Lubanska**, Windsor (CA); **Espanta
Jalili**, Windsor (CA)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/987,769**

(22) Filed: **Aug. 30, 2013**

(65) **Prior Publication Data**

US 2014/0109244 A1 Apr. 17, 2014

Related U.S. Application Data

(60) Provisional application No. 61/695,719, filed on Aug.
31, 2012, provisional application No. 61/743,501,
filed on Sep. 6, 2012.

(51) **Int. Cl.**
A61K 49/00 (2006.01)
A01K 67/027 (2006.01)

(52) **U.S. Cl.**
CPC **A01K 67/0278** (2013.01); **A01K 67/0275**
(2013.01); **A61K 49/0008** (2013.01); **A01K**
2217/052 (2013.01); **A01K 2227/105** (2013.01);
A01K 2267/0331 (2013.01)

(58) **Field of Classification Search**
CPC **A01K 67/0278**; **A01K 67/0275**; **A61K**
49/0008

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,736,866 A 4/1988 Leder et al.
5,925,803 A 7/1999 Leder et al.

OTHER PUBLICATIONS

Evangelia Kirou ("Elucidating the Role of Spy1A during cMyc
Induced Mammary Tumor Development" Jan. 1, 2011; Electronic
Theses and Dissertations. Paper 290, Windsor Canada).
Clontech pTRE-Tight Vector Specification Sheet (Jul. 28, 2010).
Kirou, Evangelia, "Elucidating the Role of Spy1A during c-Myc
Induced Mammary Tumor Development" (2011). Electronic Theses
and Dissertations. Paper 290. Windsor, Canada.
Blakely, Collin, M. et al., "Developmental stage determines the
effects of MYC in the mammary epithelium", Development, 132
(2005): 1147-1160, the Company of Biologists.

* cited by examiner

Primary Examiner — Scott Long

(57) **ABSTRACT**

In one aspect, the invention provides a transgenic non-human
animal model having germ cells and somatic cells contain-
ing an endogenous MMTV-SV40-Spy1A gene sequence
introduced into said animal model or an ancestor of said
animal model at an embryonic stage, wherein said gene
sequence comprises a mouse mammary tumor virus gene
(MMTV), a functionally disrupted SV40 gene (SV40) and a
human Spy1A gene. In another aspect, the present invention
provides a transgenic non-human animal model whose germ
cells and somatic cells contain an endogenous Spy1A-pTRE-
Tight gene sequence introduced into said animal model or an
ancestor of said animal model at an embryonic stage. Prefer-
ably, the Spy1A-pTRE-Tight animal model expresses the
Spy1A gene and develop cancer, preferably breast cancer,
when administered with tetracycline, preferably doxycycline.

9 Claims, 15 Drawing Sheets

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 24




Figure 25




Figure 26




Figure 27




Figure 28





Figure 29



MMTV-SV40-SPY1A AND SPY1A-PTRE TRANSGENIC MOUSE MODELS

RELATED APPLICATIONS

This application claims the benefit of 35 U.S.C. 119(e) to U.S. Provisional Patent Application Ser. No. 61/695,719 filed on Aug. 31, 2012 and U.S. Provisional Patent Application Ser. No. 61/743,501 filed on Sep. 6, 2012.

SCOPE OF THE INVENTION

In one aspect, the present invention provides a transgenic non-human animal model [BF1] which is selected to overexpress Spy1A under the control of a MMTV promoter causing the animal model to develop cancer, and preferably breast cancer. In another aspect, the present invention provides a transgenic non-human animal model selected to express Spy1A in one or more tissues thereof when an antibiotic is fed to the animal, and leading to the development of cancer, most preferably breast cancer. In another aspect, the present invention provides a transgenic non-human animal model, preferably a mammal and most preferably a mouse model, which includes a MMTV-SV40-Spy1A gene sequence (hereinafter referred interchangeably as "MMTV-SV40-Spy1A", "MMTV-SV40-Spy1", "MMTV-Spy1A" and "MMTV-Spy1"). The animal model of the invention may permit uses in the identification of agents for inhibiting or treating cancer, or namely breast cancer.

BACKGROUND OF THE INVENTION

Amid all cancers known to afflict the Canadian population, breast cancer (BC) is documented as the second leading cause of cancer deaths among females. Current knowledge of the molecular signatures and biochemical pathways that govern BC initiation and progression is far from comprehensive and requires further expansion in order to identify putative biomarkers that undoubtedly predict the correct therapeutic course of action to take with each patient. Due to the heterogeneous nature of cell types which cooperate to form a functional post-natal mammary gland, the various clinical forms of BC that may arise are currently distinguished based on prognostic criteria such as histological phenotype, steroid and growth factor receptor status, and tumor ability to metastasize to neighbouring lymph nodes. In order to fully understand the various molecular mechanisms underpinning the evolution of mammary tumorigenesis, post-pubertal mammary gland development is often looked upon to highlight critical signaling pathways that possess the inherent capacity to mutate and/or become deregulated in BC. Once maturity is established, the adult virgin mammary organ retains the ability to cycle through four development stages: virgin, pregnancy, lactation, followed by involution and reversion to a virgin-like state. During early pregnancy-induced lobuloalveolar development, elevated expression of prolactin, placental lactogens, and progesterone results in escalated rates of luminal epithelial proliferation, and promotes functional differentiation of alveolar precursor cells into specialized structures proficient in milk release. Parturition-induced lactogenesis functions to nourish neonates through alveolar milk production and secretion of colostrums into enlarged luminal ducts. Neonate weaning initiates extensive luminal alveolar cell death (apoptosis) and epithelial remodelling during involution, a process lasting for several days to allow for reinstatement of the mammary gland to a virgin-like appearance.

SUMMARY OF THE INVENTION

It has been appreciated that at a cellular level Speedy (Spy1A) plays a role in the DNA damage response, functioning to enhance cell survival and promote cell proliferation in lieu of apoptosis. Spy1A is capable of promoting precocious development and tumorigenesis. Hence, determining how Spy1A protein levels are regulated may reveal novel information regarding the dynamics of cell cycle control during normal and abnormal growth conditions. Furthermore, non-degradable forms of Spy1A do not trigger intrinsic cell cycle checkpoints but, rather, promote cell proliferation and oncogenic cell transformation demonstration that this mechanism may contribute to tumorigenesis.

Further, it has been appreciated that Spy1A is a novel cell cycle gene whose product binds to cyclin-dependent kinase-2 (CDK2) and activates its kinase activity to promote cell cycle progression through a cyclin independent mechanism and to promote cell movement into DNA synthesis. Spy1A is expressed naturally at high levels in the proliferating mammary gland, and aberrant overexpression of Spy1A results in precocious mammary development and eventually tumorigenesis in vivo.

Spy1A elevation in c-Myc overexpressing tumors can be maintained during primary tumor culture, the MMTV-Myc mouse model, well documented for its ability to form aggressive mammary adenocarcinomas, may be utilized to derive a previously uncharacterized tumor cell line engineered to overexpress c-Myc (henceforth referred to as F5A1-2).

Induction of the mammary oncogene c-Myc upregulates Spy1A and it is further demonstrated that Spy1A protein levels are elevated in mammary tissue and breast tumors derived from MMTV-Myc transgenic mice. Spy1A knock-down in F5A1-2 cell lines led to downregulation of cyclin-dependent kinase inhibitors (CKI) p21 and p27, a 23% reduction in proliferation rate, and a shift in cellular phenotype to a spindle-like/fibroblastic morphology. Together, findings support that Spy1A plays a functional role in mammary-related c-Myc signal transduction, and acts downstream of ER α , c-Myc, and the MAPK cascade to regulate proliferation, mammary development, and carcinogenesis.

One possible non-limiting object of the present invention is to provide a powerful tool for the study of cancer, namely breast cancer. Specifically, in one aspect the invention provides a transgenic non-human animal model whose somatic cells contain at least one copy of a MMTV-Spy1 transgene causing Spy1A overexpression under the control of the MMTV promoter, and causing this animal model to develop cancer, or more particularly breast cancer. The animal is preferably hemizygous for the transgene.

In another aspect, the present invention provides a transgenic non-human animal model whose somatic cells contain a MMTV-Spy1A transgene which causes the animal model to develop cancer, or preferably breast or liver cancer.

In yet another aspect, the present invention provides a transgenic non-human animal model comprising germ cells and somatic cells containing an exogenous MMTV-SV40-Spy1A gene sequence introduced into said animal model or an ancestor of said animal model at an embryonic stage, wherein said gene sequence comprises a mouse mammary tumor virus gene (MMTV), a functionally disrupted SV40 gene (SV40) and a human Spy1A gene. It has been appreciated that a portion of an SV40 gene when incorporated into a transgenic construct, or preferably the MMTV-SV40-Spy1A gene sequence increases expression or induce overexpression of a gene under the control of a MMTV promoter.

In a preferred embodiment, the transgenic non-human animal comprises germ cells and somatic cells containing an exogenous MMTV-SV40-Spy1A gene sequence introduced into said animal or an ancestor of said animal, at an embryonic stage wherein said gene sequences comprises a mouse mammary tumor virus promoter, a functionally disrupted SV40 gene and a human Spy1A gene.

Preferably, the animal model is hemizygous of the MMTV-SV40-Spy1A gene sequence. The human Spy1A gene preferably includes a modified Spy1A gene of SEQ ID NO: 1 or a conservatively modified variant thereof. Most preferably, the MMTV-SV40-Spy1A gene sequence is introduced to the animal model or the ancestor by microinjecting a fragment sequence obtained from restriction enzyme digestion of SEQ ID NO: 5 or a conservatively modified variant thereof with XhoI and SpeI.

In yet another aspect, the present invention provides a transgenic non-human animal model which is selected to express Spy1A in one or more tissues thereof when an antibiotic is fed to the animal model, said expression of Spy1A preferably leading to the development of cancer within said animal model, preferably breast or liver cancer.

In yet another aspect, the present invention provides a transgenic non-human animal model whose germ cells and somatic cells contain an exogenous Spy1A-pTRE-Tight gene sequence (hereinafter interchangeably referred to as "Flag-Spy1A-pTRE", "Flag-Spy1A-pTRE-Tight", "Flag-Spy1-pTRE", "Flag-Spy1-pTRE-Tight", "Spy1A-pTRE", "Spy1A-pTRE-Tight", "Spy1-pTRE" and "Spy1-pTRE-Tight") introduced into the animal model or an ancestor of the animal model at an embryonic stage, wherein said gene sequence comprises a human Spy1A gene.

Preferably, the animal model is hemizygous of the Spy1A-pTRE-Tight gene sequence. The human Spy1A gene is preferably a modified Spy1A gene of SEQ ID NO: 1 or a conservatively modified variant thereof. Most preferably, the Spy1A-pTRE-Tight gene sequence is introduced to the animal model or the ancestor by microinjecting a fragment sequence obtained from restriction enzyme digestion of SEQ ID NO: 18 or a conservatively modified variant thereof with XhoI and A1wNI.

In a preferred embodiment, the animal model is selected to express the Spy1A gene and develop cancer when administered with a tetracycline. Most preferably, the tetracycline is doxycycline. Preferably, the cancer is breast or liver cancer.

The animal model of the present invention is not strictly limited to those belonging to any specific genus or species, provided that the animal model preferably permits introduction of exogenous genetic sequences to be incorporated into the genome. The animal model is preferably a mouse, a rat, a monkey, a sheep, a dog, a rabbit, or a horse. Most preferably, the animal model is a mouse or a rat.

In yet another aspect, the present invention provides a method of producing the transgenic non-human animal, the method comprising microinjecting the fragment sequence into a fertilized embryo and transplanting said fertilized embryo into a surrogate animal.

In yet another aspect, the present invention provides a tumor cell line comprising a plurality of cells, wherein the cells are derived from the animal model or comprise the fragment sequence.

In yet another aspect, the present invention provides a method for screening an agent for treating or preventing cancer, the method comprising administering the agent into the animal model or the tumor cell line and detecting size reduction of a tumor caused by the cancer. Preferably, the cancer is breast or liver cancer.

In yet another aspect, the present invention provides a transgenic non-human animal model comprising germ cells and somatic cells having an endogenous MTB-Spy1A gene sequence, wherein the animal model is a progeny generated by crossing a MMTV-rtTA non-human animal model and the animal model having the Spy1A-pTRE-Tight gene sequence derived from the fragment sequence obtained from restriction enzyme digestion of SEQ ID NO: 18 or a conservatively modified variant thereof with XhoI and A1wNI, the progeny being selected to express the Spy1A gene when administered with a tetracycline.

Preferably, the conservatively modified variants have at least 70%, 75%, 80%, 85%, 90%, 95% or 99% sequence identity to the specific referenced nucleotide or amino acid sequence. The conservatively modified variants may include point mutations, as well as deletions, substitutions, insertions, transitions, amplifications, inversions, transversions or others of one or more nucleotide bases or amino acid residues.

BRIEF DESCRIPTION OF THE DRAWINGS

Reference may now be had to the following detailed description, taken together with the accompanying drawings in which:

FIG. 1 shows a fusion gene fragment construct for producing a transgenic mouse according to an embodiment of the present invention.

FIG. 2 shows identification of positive founders confirmed through PCR analysis. Positive founders are indicated by the presence of an 825 bp fragment.

FIG. 3 shows GAPDH (100 bp) control for the identification of positive founders as shown in FIG. 2.

FIG. 4 shows identification of SDM-derived mutant Flag-Spy1A-pLXSN constructs upon detecting of a 977 bp fragment following EcoRI digestion of isolated plasmid DNA from each colony: colony 1.1 (lane 1); colony 1.2 (lane 2); colony 1.3 (lane 3); colony 2.1 (lane 4); colony 2.2 (lane 5); and colony 2.3 (lane 6). The pLXSN vector backbone was estimated at 7.0 kb, and the Spy1A insert was estimated at 1.0 kb (997 bp).

FIG. 5 shows EcoRI digestion of the MMTV-SV40-Spy1A transgenic vector releasing the flag-Spy1A coding sequence from the remaining vector backbone. EcoRI digestion of the resultant transgene DNC produced a 977 bp fragment as expected and confirmed successful cloning. The pMMTV-SV40 backbone was estimated at 6.0 kb and the flag-tagged Spy1A insert was estimated at 1.0 kb (997 bp).

FIG. 6 shows digestion of MMTV-SV40-Spy1A prior to microinjection.

FIG. 7 shows detection of a single copy of MMTV-SV40-Spy1A DNA utilizing PCR genotyping methods. Transgene DNA was successfully detected using 8% PAGE in order to verify the success of using the MO23/MO23 primer set for detection of the Spy1A transgene in tail clip samples. PCR amplification of MMTV-SV40-Spy1A vector DNA (lane 2) using MO22/MO23 primers produced an 825 bp amplicon, identical to the positive MMTV vector control (+MMTV, lane 1) as expected.

FIG. 8 shows successful transmission of transgene from founder to offspring using primer pair MO22 (SEQ ID NO: 2)/MO23 (SEQ ID NO: 4) resulting in a 825 bp fragment.

FIG. 9 shows confirmation of germline transmission of transgene using primer pair A933 (SEQ ID NO: 3)/MO23 (SEQ ID NO: 4) resulting in a 197 bp fragment.

FIG. 10 shows a Spy1-pTRE vector map according to an embodiment of the present invention.

FIG. 11 shows a restriction digest of XhoI and AlwNI for isolating a portion of the vector illustrated FIG. 10 for a subsequent microinjection step according to an embodiment of the present invention.

FIG. 12 shows identification of Spy1-pTRE founder mice via PCR analysis in the presence of a 536 bp band. The number labels correspond to mouse tag numbers belonging to each tail sample screened, and the label “vector” corresponds to the Spy1-pTRE transgenic vector used as a positive control.

FIG. 13 shows confirmation of successful germline transmission of Spy1-pTRE transgene according to an embodiment of the present invention. The number labels correspond to mouse tag numbers belonging to each tail sample screened, and the label “vector” corresponds to the Spy1-pTRE transgenic vector used as a positive control.

FIG. 14 shows a Flag-Spy1A-pTRE Tight vector map according to an embodiment of the present invention. Primers, Spy1 and pTRE promoter are outlined.

FIG. 15 shows a linearized map of a Flag-Spy1A-pTRE Tight vector indicating the locations of promoter, Spy1 and primers.

FIG. 16 shows a 4.25% polyacrylamide gel image of Spy1-pTRE DNA samples 1, 2 and 3 amplified with PCR using the primer combination A548/A549 with 0.5 second exposure time. The lane “L” corresponds to a ladder; the lanes 1P, 2P and 3P correspond to samples 1, 2 and 3, respectively; the lane “CP” corresponds to pTRE vector control (447 bp); and the lanes “G” correspond to GAPDH (about 100 bp).

FIG. 17 shows a 4.25% polyacrylamide gel image of Spy1-pTRE DNA samples 1, 2 and 3 amplified with PCR using the primer combination A548/A549 with 1 second exposure time. The lane “L” corresponds to a ladder; the lanes 1P, 2P and 3P correspond to samples 1, 2 and 3, respectively; the lane “CP” corresponds to pTRE vector control (447 bp); and the lanes “G” correspond to GAPDH (about 100 bp). The band of correct size is outlined under the lane “3P”.

FIG. 18 shows a 4.25% polyacrylamide gel image of Spy1-pTRE DNA samples 1, 2 and 3 amplified with PCR using the primer combination A548/A549 with 2 second exposure time. The lane “L” corresponds to a ladder; the lanes 1P, 2P and 3P correspond to samples 1, 2 and 3, respectively; the lane “CP” corresponds to pTRE vector control (447 bp); and the lanes “G” correspond to GAPDH (about 100 bp). The band of correct size is outlined under the lane “3P”.

FIG. 19 shows a 4.25% polyacrylamide gel image of Spy1-pTRE DNA samples 1, 2 and 3 amplified with PCR using the primer combination A548/A549 with 3 second exposure time. The lane “L” corresponds to a ladder; the lanes 1P, 2P and 3P correspond to samples 1, 2 and 3, respectively; the lane “CP” corresponds to pTRE vector control (447 bp); and the lanes “G” correspond to GAPDH (about 100 bp). The band of correct size is outlined under the lane “3P”.

FIG. 20 shows a 4.25% polyacrylamide gel image of Spy1-pTRE DNA samples 1, 2 and 3 amplified with PCR using the primer combination A548/A549 with 0.5 second exposure time. The lane “L” corresponds to a ladder; the lanes 1P, 2P and 3P correspond to samples 1, 2 and 3, respectively; the lane “CP” corresponds to a maxi-prepped pTRE vector control with a higher concentration; and the lanes “G” correspond to GAPDH. The band of correct size is outlined under the lane “3P”.

FIG. 21 shows a 4.25% polyacrylamide gel image of Spy1-pTRE DNA samples 1, 2 and 3 amplified with PCR using the primer combination A548/A549 with 1 second exposure time. The lane “L” corresponds to a ladder; the lanes 1P, 2P and 3P correspond to samples 1, 2 and 3, respectively; the lane

“CP” corresponds to a maxi-prepped pTRE vector control with a higher concentration; and the lanes “G” correspond to GAPDH. The band of correct size is outlined under the lanes “1P” and “3P”.

FIG. 22 shows a 4.25% polyacrylamide gel image of Spy1-pTRE DNA samples 1, 2 and 3 amplified with PCR using the primer combination A548/A549 with 2 second exposure time. The lane “L” corresponds to a ladder; the lanes 1P, 2P and 3P correspond to samples 1, 2 and 3, respectively; the lane “CP” corresponds to a maxi-prepped pTRE vector control with a higher concentration; and the lanes “G” correspond to GAPDH. The band of correct size is outlined under the lanes “1P” and “3P”.

FIG. 23 shows a bar graph illustrating the results from a qRT PCR analysis test for Spy1 overexpression in the mammary glands of a MMTV-Spy1 mouse in accordance with a preferred embodiment of the invention, and which shows log10 expression of Spy1 as the Y axis compared to GAPDH.

FIG. 24 shows a DMBA treatment plan for a MMTV-Spy1 mouse and its pair matched littermates, and which indicates age at beginning and end treatment.

FIG. 25 shows a bar graph depicting the percentage of MMTV-Spy1 and control mice (Y axis) that developed all tumour types, mammary tumours, and ovarian tumours.

FIG. 26 shows a line graph depicting the percentage of tumour free mice (Y axis) at the indicated ages in weeks (X axis).

FIG. 27 shows a bar graph depicting the percentage of MMTV-Spy1 and pair matched littermates (F1 cntl) developing hepatocellular carcinoma 1 year of age and older.

FIG. 28 shows a bar graph illustrating the results from a qRT PCR conducted on liver tissue collected from MMTV-Spy1 mice and their pair matched littermates, and which illustrates Spy1 expression on a log10 scale as compared to GAPDH.


FIG. 29 shows a bar graph illustrating the results from a qRT PCR confirming Spy1 overexpression upon delivery of doxycycline to a MTB-Spy1 mouse generated by crossing a Spy1-pTRE mouse with a MMTV-rtTA mouse.

DETAILED DESCRIPTION OF THE INVENTION

The gene fragment construct MMTV-SV40-Spy1A (SEQ ID NO: 5) for the development of a transgenic mouse according to a preferred embodiment of the present invention is shown in FIG. 1. The construct was micro injected at roughly 4.7 kb into 357 fertilized embryos from superovulated female mice and transplanted into pseudo pregnant CD-1 female mice. This resulted in 43 pups being born of which 13 tested positively for the MMTV-SV40-Spy1A as confirmed in the PCR analysis shown in FIGS. 2 and 3.

To prepare the MMTV-SV40-Spy1A construct, Flag-Spy1A-pLXSN containing the complete coding sequence of the human Spy1A gene conjugated to a flag tag was provided. Site-directed mutagenesis (SDM) was utilized to create a second EcoRI site positioned near the terminal region of the human Spy1A coding sequence (SEQ ID NO: 1) in Flag-Spy1A-pLXSN for efficient removal of the intrinsic poly-A tail.

GAATTCGCGGCCGCGCTCGACCTGCGACGAGCCTTGACCGCGCTTGCCCGGCCCTCTCCC
 GCGCAGCCCCGGGCTTCGCGAGGAATATTGGGAAACAAAATGAGGCACAATCAGATGTG
 TTGTGAGACACCACCTACTGTCTACTGTTTATGTAAATCAGGGTCAAATAGATCACATCA
 GCCTAAAAAGCCCATTACTCTGAAGCGTCCTATTTGTAAAGATAATTGGCAAGCATTGTA
 AAAAAATACACATAATAACAACAAATCTAAACGCCCCAAAGGACCTTGTCTGGTTATACA
 GCGTCAGGATATGACTGCTTTCTTTAAATTATTTGATGACGATTAAATCAAGATTCTTT
 GTGGATGGACTGCTGCTGTAAATTCAGACAAGTATCTTTTGGCTATGACCTTTGTTTA
 TTTCAGAGGGCTAAATTTACTATAAGTGAGCATACCAGGATAAATTTCTTTATTGCTCT
 GTATCTGGCTAATACAGTTGAAGAAGATGAAGAAGAAACCAAGTACGAAATTTTCCATG
 GGCTTTAGGGAAAACTGGAGAAAATTGTTCCCTAATTTCTTAAAGTTAAGGGACCAGCT
 CTGGGATAGAATTGACTATAGGGCTATTGTAAGCAGGCGATGTTGTGAGGAGGTTATGGC
 CATTGCACCAACCCATTATATCTGGCAAAGAGACGTTCTGTTTCATCAGTGGAGCTGT
 CAGAACTACAACAGAGATGAAGTTCAGCTGCCCCGGGGACCTAGTGCCACACCAGTAGA
 TTGTTCACTCTGTGGTAAAAAAGAAGATATGTTAGACTGGGATTGTCTTCATCATCATC
 TTTATCCAGTCATACAGCAGGGGTGACAGAAAAACATTCTCAGGACTCATACAACCTCACT
 GTCATGGACATAATAGGTGATCCTTCTCAAGCTTATACTGGTTCTGAAGGTATGATATA
 GTAATA


 TGCCGAAATTA GATTATGTCATGTTGTTTACTGAGCTCTAGTCAGTCCTTTCTGGCGGGG
 ATACATAATAATTTATATACTCCAACAATATGAGTTAAATTAATCTTGAAACTTTCTCCC
 CTTTCAGTTACTTTTGTCTTGTGTCCATATTGTTTGTGGTGACCCACCTAAACAGAT
 TTTTAATGTGACCTATGTTAAGTTGAAACTAATGCACCATAAGCCTCAGTATTTTAAGA
 GCCTGAATCATTTTTTTGAAATGTTTATTTATTCAAAGGGTTTCAAGAAGAAATAAA
 TTTACTTGTAATCTCAAAAAAAAAAAAAAAAAAAAAA

SDM primers A424 and A425 (SEQ ID NOs: 6 and 7) were designed to flank the vector region targeted for mutation. SDM reactions were performed with the following components: Flag-Spy1A-pLXSN vector DNA (10-100 ng); 0.3 mM dNTP mix (Cat. No. DD0057, Biobasic Inc., Ontario, Canada); 1× pfx buffer and 1 µl pfx polymerase (Cat. No. 11708-013, Invitrogen, Canada); 1 mM MgSO₄; 1 µM each of A424 forward and A425 reverse primers (SEQ ID NOs: 6 and 7); filter-sterilize nuclease free water up to 50.0 µl. Cycling conditions for SDM include (1) 2 minutes at 94° C., (2) 25 cycles of 94° C. for 15 seconds, 55° C. for 30 seconds and 68° C. for 5 seconds, and (3) 68° C. for 10 minutes. SDM reaction products were DpnI digested for 2 hours at 37° C. (Cat. No. ER1701, Fermentas, Burlington, Ontario, Canada), and subsequently transformed utilizing TOP10 *E. coli* and plated onto 100 mg/ml Ampicillin plates. Select colonies were screened for EcoRI insertion and were identified upon detection of a 977 bp fragment following EcoRI digestion (for 20 minutes at 37° C. (Cat. No. FD0274, Fermentas)) of isolated plasmid DNA from each colony (using QIAprep Spin Miniprep Kit (Cat. No. 27104, Qiagen, Mississauga, Ontario, Canada) as shown in FIG. 4. Successful EcoRI insertion was confirmed through sequencing for two colonies in particular, Is.1 and IIs.3, utilizing A210 and A211 sequencing primers (SEQ ID NOs: 8 and 9). Purified vector DNA from Colony IIs.3 was

subjected to EcoRI digestion (Cat. No. ER0271, Fermentas), and produced two fragments at 7.0 kb (vector backbone) and 1.0 kb (Spy1A gene insert). Digestion products were separated, and the appropriate 1.0 kb fragment was gel extracted using the EZ-10 Spin Column DNA Gel Extraction Kit (Cat. No. BS354, Biobasic Inc.) and purified.

EcoRI digestion of 2 mg of MMTV-SV40-TRPS-1 vector DNA ensued for 1 hour at 37°, followed by the immediate removal of terminal phosphate groups from digested ends utilizing incubation with calf intestinal alkaline phosphatase (Cat. No. EF0341, Fermentas) for 30 minutes at 37°. Phosphatase treatment was necessary in order to prevent the religation of linearized vector DNA termini. Consequently, reaction products were separated, followed by gel purification of the resultant 6.0 kb fragment (MMTV-SV40 backbone) using the EZ-10 Spin Column DNA Gel Extraction Kit. Ligation of the Spy1A gene insert into the MMTV-SV40 backbone was conducted using T4 DNA ligase (Cat. No. EL0017, Fermentas), and ligation reactions were subsequently transformed utilizing TOP10 *E. coli* and plated onto 100 mg/ml Ampicillin plates. Select colonies were screened for EcoRI insertion and were identified upon detection of a 977 bp fragment following EcoRI digestion of isolated plasmid DNA from each colony as shown in FIG. 5. Successful cloning of the Spy1A coding sequence into the MMTV-SV40

vector backbone was confirmed through sequencing. Sequencing primers A252, A253, A254, A255, A256, A257, A258 and A259 (SEQ ID NOs: 10 to 16) were utilized in order to verify the intactness of all transgenic vector components.

The resultant transgenic vector was designated as MMTV-SV40-Spy1A and contains an untranslated portion of the Ha-ras gene, in addition to an SV40 polyadenylation site. Bacterial sequences such as those found in vector backbones have been noted to inhibit successful incorporation of transgenic DNA into the mouse blastocyst genome. Thus, XhoI/SpeI double digestion (Cat. Nos. ER0691 and ER1251, Fermentas) of purified vector DNA (30 mg per tube) ensued, and resulted in the production of two fragments: 4.7 kb (MMTV-SV40-Spy1A transgene) and 2.9 kb (remaining backbone) as shown in FIG. 6. Two vials of XhoI/SpeI digested transgenic DNA were made available for microinjection into mouse blastocysts for subsequent creation of the first MMTV-SV40-Spy1A transgenic mouse model known to date. Transgene detection of a single copy of MMTV-SV40-Spy1A DNA was tested utilizing the PCR conditions outlined for MO22 and MO23 genotyping primers (SEQ ID NOs: 2 and 4) as shown in FIG. 7.

The resulting transgene fragment was sent to the University of Western Ontario Transgenic Facility to undergo pronuclear injections. Tail samples from the resulting litters were received and DNA was extracted using the Qiagen Puregene Core Kit A for mouse tails. Transgene detection was accomplished using two sets of primers with two unique forward primers (MO22 (SEQ ID NO: 2) and A933 (SEQ ID NO: 3)) and one reverse primer (MO23 (SEQ ID NO: 4)). PCR cycling conditions consisted of (1) denaturation at 94° C. for 3 min, (2) denaturation at 94° C. for 1 min, annealing at 55° C. for 2 min, elongation at 72° C. for 1 min and (3) a final elongation step at 72° C. for 3 min. Each 25 uL PCR reaction was made using UBI HP Taq DNA polymerase (HPTAQ-01) and contained a final concentration of 2 ng/uL of pure genomic DNA, 1× buffer, 2 mM MgSO₄, 0.2 mM dNTP, 0.5 mM forward primer, 0.5 mM reverse primer and 0.025U/uL Taq polymerase. Additionally, a final volume of 1% and 4% DMSO was added for primer pairs MO22 (SEQ ID NO: 2)/MO23 (SEQ ID NO: 4) and A933 (SEQ ID NO: 3)/MO23 (SEQ ID NO: 4) respectively. PCR amplification resulted in an 825 bp and 197 bp amplicon for primers MO22 (SEQ ID NO: 2)/MO23 (SEQ ID NO: 4) and A933 (SEQ ID NO: 3)/MO23 (SEQ ID NO: 4) respectively as shown in FIGS. 8 and 9, respectively.

Expression levels of Spy1A was tested in the inguinal mammary glands of 6 week old MMTV-Spy1A mice and their negative littermates via qRT PCR analysis to ensure Spy1A was being overexpressed in the mammary gland of this mouse model system. Spy1A was found to be significantly overexpressed in the mammary glands of MMTV-Spy1A mice as compared to their control littermates (FIG. 23). To test for increased susceptibility to mammary tumorigenesis, MMTV-Spy1A mice and their negative littermates were treated with 1 mg of 7,12-dimethylbenzanthracene (DMBA) once a week for 6 consecutive weeks beginning at 8 weeks of age via oral gavage. Treatment plan indicating age during treatment and at end of study is illustrated in FIG. 24. Mice were monitored on a weekly basis for the development of mammary tumours via palpitation. MMTV-Spy1A mice were found to develop significantly more mammary tumours than their control littermates (FIG. 25). Additionally, MMTV-Spy1A mice developed tumours earlier than their control littermates (FIG. 26).

When collecting male MMTV-Spy1 mice over the age of 1 year, it was noted there was an increased incidence of liver

carcinogenesis in the MMTV-Spy1 mice as compared to their negative control littermates (FIG. 27). Liver tissue was collected from MMTV-Spy1 male mice 1 year of age and older along with pair matched littermate controls and the liver tissue was subjected to qRT PCR analysis to determine Spy1 expression in the liver. Spy1 was found to be significantly overexpressed in MMTV-Spy1 male mice as compared to littermate controls (FIG. 28).

In accordance with another preferred embodiment of the present invention, the fusion gene fragment construct Flag-Spy1A-pTRE-Tight (SEQ ID NO: 18) as illustrated in FIGS. 10, 14 and 15 were prepared. In particular, a Caspase3-pTRE-Tight vector was digested with EcoRI and PvuII to remove Caspase3. A 20 bp linker was then added to close the vector. Site directed mutagenesis was performed on a Flag-Spy1A-pLXSN vector to create an EcoRI restriction enzyme site to enable extraction of Flag-Spy1A from the vector. EcoRI digestion was subsequently performed to remove Flag-Spy1A from the Flag-Spy1A-pLXSN vector. The Flag-Spy1A fragment was then ligated into the pTRE-Tight vector.

Successful preparation of DNA fusion gene fragment construct samples were confirmed by PCR amplification with the primer combination A548/A549 (SEQ ID NOs: 19 and 20) and polyacrylamide gel (as shown in FIGS. 16 to 22) as well as DNA sequencing. The bands of correct size are outlined under the lanes "1P" and/or "3P" in FIGS. 17 to 22. All tested PCR samples were confirmed by DNA sequencing.

The Spy1-pTRE plasmid were restriction digested using XhoI and A1wNI to isolate a portion for subsequent microinjection into a fertilized embryo from a superovulated female mouse. The digested portion was confirmed by gel electrophoresis as shown in FIG. 11. The digested portion was microinjected into fertilized embryos from superovulated female mice and transplanted into pseudo pregnant CD-1 female mice. Some resulting pups tested positive as confirmed and shown in FIG. 12. Successful germline transmission of the Spy1-pTRE transgene was confirmed as shown in FIG. 13.

The mice having the Spy1-pTRE gene sequence was fed doxycycline to activate expression of Spy1A. Development of cancer including breast cancer was experimentally confirmed.

In a separate study, selected Spy1A-pTRE mice found to lack inducible overexpression of Spy1A were nevertheless found to be suitable for preparing overexpressing progenies. In a controlled study, selected Spy1-pTRE mice found to be without inducible overexpression of Spy1A were preferably crossed with MMTV-rtTA mice to generated a MTB-Spy1 mouse model. It has been appreciated that such animal model may permit inducible overexpression of Spy1A preferably after administration of doxycycline to their diet in the form of food pellets. Indeed, expression of Spy1 was induced by administering 2 mg/mL of doxycycline at 5 weeks of age. Mammary glands were collected at 6 weeks of age from MTB-Spy1, Spy1-pTRE and MMTV-rtTA mice for qRT analysis to test for increased expression of Spy1 in the MTB-Spy1 mouse as compared to the selected control Spy1-pTRE and MMTV-rtTA mice. Spy1 was found to be overexpressed in the MTB-Spy1 mouse, indicating this model system is functioning correctly (FIG. 29).

The applicant has appreciated that the present invention provides various advantages and applications, and which include without restriction a transgenic non-human animal model whose somatic cells contain at least one copy of a MMTV-Spy1A transgene causing the animal model to develop cancer.

11

In yet another aspect, the present invention provides a transgenic non-human animal model all of whose germ cells and somatic cells contain an exogenous MMTV-SV40-Spy1A gene sequence introduced into said mammal, or an ancestor of said mammal, at an embryonic stage wherein said gene sequence comprises a mouse mammary tumor virus gene (MMTV), a functionally disrupted SV40 gene (SV40) and a modified human Spy1A gene of SEQ ID NO: 1.

Other applications of the invention include without restriction:

Methods of screening drugs/vaccines/or other vehicles developed for the prevention of the development of cancer;

The study environmental factors and their effects on the development of cancer;

The study cancer initiated at various stages of the animals development;

Methods of screening drugs candidates and their anti-carcinogenic;

Methods of screening drugs/vaccines/or other vehicles developed for the prevention of the development of cancer;

The study environmental factors and their effects on the development of cancer; and

The study of cancer namely breast cancer based on a novel expression of Spy1A initiated within a model animal by feeding the animal doxycycline.

Additional applications of the invention include, without restriction:

1. Expression of Spy1 A within one or more tissues of the model animal is activated by the animal model ingesting doxycycline (Dox).

12

2. The expression of Spy1A results in the tissues of the animal model results in the development of cancer namely breast cancer within that model animal.

3. A transgenic non-human animal model in this case being a mouse incorporates the condition and promoter response of claims 1 and 2.

4. The mouse animal model is able to pass this condition expressed in claims 1 and 2 along to subsequent generations when cross with a mouse not having this condition.

5. The transgenic non-human animal of claim 1, can be said animal selected from the group consisting of mice, rats, monkeys, sheep, and rabbits.

6. Analysis of animal model DNA is able to confirm that transgenic condition exists in said animal model.

7. Transgenic animal model may be used to:

a. Study cancer

b. Study cancer initiated at various stages of the animals development

c. Method of screening drugs candidates and there anti-carcinogenic

d. Method of screening drugs/vaccines/or other vehicles developed for the prevention of the development of cancer.

e. Study environmental factors and their effects on the development of cancer

INCORPORATION BY REFERENCE

Incorporated herein by reference are two replacement compact discs and a further duplicate compact disc in Computer Readable Form each identically containing a single file named "sequence_listing.txt" created on Dec. 9, 2013 and which is 21 KB in size.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 20

<210> SEQ ID NO 1

<211> LENGTH: 1303

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

```

gaattcgcg cgcgctcgac ctgcgacgga gccttgaccg cegttgcccg gccctctccc      60
gcgcagcccc gggcttcgcg aggaatattg ggaacacaaa atgaggcaca atcagatgtg      120
ttgtgagaca ccacctactg tcaactgttta tgtaaaatca gggtaaata gatcacatca      180
gcctaaaaag ccctactact tgaagcgctc tatttgtaaa gataattggc aagcatttga      240
aaaaaataca cataataaca acaaatctaa acgccccaaa ggacctgtgc tggttataca      300
gcgtcaggat atgactgctt tctttaaatt atttgatgac gatttaattc aagatttctt      360
gtggatggac tgctgctgta aaattgcaga caagtatctt ttggctatga cctttgttta      420
tttcaagagg gctaaattta ctataagtga gcataccagg ataaatttct ttattgctct      480
gtatctggct aatacagttg aagaagatga agaagaaacc aagtacgaaa tttttccatg      540
ggctttaggg aaaaactgga gaaaattgtt ccctaatttc ttaaagttaa gggaccagct      600
ctgggataga attgactata gggctattgt aagcaggcga tgttgtaggg aggttatggc      660
cattgcacca accattata tctggcaaag agaagcttct gttcatcaca gtggagctgt      720
cagaaactac aacagagatg aagttcagct gccccgggga cctagtgcc aaccagtaga      780
ttgttcactc tgttgtaaaa aaagaagata tgtagactg ggattgtctt catcatcatc      840

```

-continued

```

tttatccagt catcacgcag gggtagacaga aaaacattct caggactcat acaactcact    900
gtcaatggac ataataggtg atccttctca agcttatact ggttctgaag gtatgatata    960
gtaatatgcc agaattcgat ttatgcatgt tgtttactga gctctagtca gtcctttctg   1020
gcggggatac ataataatth atatactcca acaatatgag ttaaattaat cttgaaactt   1080
tctccccctt cagttacttt ttgtcttggt tccatatttg tttgtgggtg acccacctaa   1140
acagatthtt aatgtgacct atgttaagtt gaaaactaat gcaccataag cctcagtatt   1200
ttaagagcct gaatcatttt ttgaaatgt ttattttatt caaaagggtt tcaagaagaa   1260
aataaattta cttgtaatct caaaaaaaaa aaaaaaaaaa aaa                      1303

```

```

<210> SEQ ID NO 2
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward primer 1 (M022)

```

```

<400> SEQUENCE: 2

```

```

cccaaggctt aagtaagttt ttgg                                           24

```

```

<210> SEQ ID NO 3
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward primer 3 (A933)

```

```

<400> SEQUENCE: 3

```

```

cccgcctctag tggcagtgtg tt                                           22

```

```

<210> SEQ ID NO 4
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse primer (M023)

```

```

<400> SEQUENCE: 4

```

```

gggcataagc acagataaaa cact                                           24

```

```

<210> SEQ ID NO 5
<211> LENGTH: 7911
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: MMTV-SV40-Spy1A fusion gene fragment construct

```

```

<400> SEQUENCE: 5

```

```

cacctaaatt gtaagcgtta atattttgtt aaaattcgcg ttaaattttt gttaaatcag    60
ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagac   120
cgagataggg ttgagtgttg ttccagtgtg gaacaagagt ccactattaa agaacgtgga   180
ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat ggcccactac gtgaaccatc   240
accctaatec agtttttttg ggtcgaggtg ccgtaaagca ctaaatecga accctaaagg   300
gagccccga tttagagctt gacggggaaa gccggcgaac gtggcgagaa aggaaggga   360
gaaagcgaaa ggagcgggcg ctaggcgctt ggcaagtgtg gcggtcacgc tgcgcgtaac   420
caccacacc gccgcgtta atgcgcgctt acagggcgcg tccattcgc cattcaggct    480

```

-continued

gcgcaactgt	tgggaagggc	gacggtgcg	ggcctcttcg	ctattacgcc	agctggcgaa	540
agggggatgt	gctgcaaggc	gattaagttg	ggtaacgcc	gggttttccc	agtcacgacg	600
ttgtaaaacg	acggccagtg	aattgtaata	cgactcacta	tagggcgaaat	tgggtaccgg	660
gccccccctc	gaggtcgacg	ctctccctta	tgcgactcct	gcattaggaa	gcagcccagt	720
agtaggttga	ggcggttgag	caccgcccgc	gcaaggaatg	gtgcatgcaa	ggagatggcg	780
cccaaacagtc	ccccggccac	ggggcctgcc	accataccca	cgccgaaaca	agcgctcatg	840
agcccgaagt	ggcgagcccg	atcttcccca	tcgggtgatgt	cggcgatata	ggcgccagca	900
accgcacctg	tggcgccggg	gatgccggcc	acgatgcgtc	cggcgtagag	gatcccaatg	960
atagagattt	tactgctcta	gttccccata	cagaattggt	tcgcttagtt	gcagcctcaa	1020
gatatcttat	tctcaaaagg	ccaggatttc	aagaacatga	catgattcct	acatctgcct	1080
gtgttactta	cccttatgcc	atattattag	gattacctca	gctaatagat	atagagaaaa	1140
gaggatctac	ttttcatatt	tctgtttctt	cttgtagatt	gactaattgt	ttagattctt	1200
ctgcctacga	ctatgcagcg	atcatagtca	agaggccgcc	atacgtgctg	ctacctgtag	1260
atattggtga	tgaaccatgg	tttgatgatt	ctgccattca	aacctttagg	tatgccacag	1320
atttaattcg	agccaagcga	ttcgctcgctg	ccattattct	gggcatactc	gctttaattg	1380
ctattatcac	ttcctttgct	gtagctacta	ctgctttagt	taaggagatg	caaactgcta	1440
cgtttgttaa	taacttctcat	aggaatgtta	cattagcctt	atctgaacaa	agaataatag	1500
atttaaaatt	agaagctaga	cttaatgctt	tagaagaagt	agtttttagag	ttgggacaag	1560
atgtggcaaa	cttaaagacc	agaatgtcca	ccagggtgtca	tgcaaattat	gatttttatct	1620
gcgttacacc	tttaccatat	aatgcttctg	agagctggga	aagaaccaa	gctcatttat	1680
tgggcatttg	gaatgacaat	gagatttcat	ataacataca	agaattaacc	aacctgatta	1740
gtgatatgag	caaacaacat	attgacacag	tggacctcag	tggcttggct	cagtcctttg	1800
ccaatggagt	aaaggcttta	aatccattag	attggacaca	atatttcatt	tttatagggtg	1860
ttggagccct	gctttttagtc	atagtgtcta	tgattttccc	cattgttttc	cagtgccttg	1920
cgaagagcct	tgaccaagtg	cagtcagatc	ttaacgtgct	tcttttaaaa	aagaaaaaag	1980
ggggaaatgc	cgcgcctgca	gcagaaatgg	ttgaactccc	gagagtgtcc	tacacctagg	2040
ggagaagcag	ccaaggggtt	gtttcccacc	aaggacgacc	cgtctgcgca	caaacggatg	2100
agcccatcag	acaaagacat	attcattctc	tgctgcaaac	ttggcatagc	tctgctttgc	2160
ctggggctat	tgggggaagt	tgcggttcgt	gctcgcaggg	ctctcaccct	tgactctttt	2220
aatagctctt	ctgtgcaaga	ttacaatcta	aacaattcgg	agaactcgac	cttctctctg	2280
aggcaaggac	cacagccaac	ttcctcttac	aagccgcac	gattttgtcc	ttcagaaata	2340
gaaataagaa	tgcttgctaa	aaattatatt	tttaccata	agaccaatcc	aataggtaga	2400
ttattagtta	ctatgttaag	aaatgaatca	ttatctttta	gtactatttt	tactcaaatt	2460
cagaagttag	aaatgggaat	agaaaataga	aagagacgct	caccctcaat	tgaagaacag	2520
gtgcaaggac	tattgaccac	aggcctagaa	gtaaaaaagg	gaaaaaagag	tgtttttgtc	2580
aaaataggag	acaggtgggtg	gcaaccaggg	acttataggg	gaccttacat	ctacagacca	2640
acagatgccc	ccttaccata	tacaggaaga	tatgacttaa	attgggatag	gtgggttaca	2700
gtcaatggct	ataaagtgtt	atatagatcc	ctcccttttc	gtgaaagact	cgccagagct	2760
agacctcctt	ggtgtatggt	gtctcaagaa	gaaaaagacg	acatgaaaca	acaggtacat	2820
gattatattt	atctaggaac	aggaatgcac	ttttggggaa	agattttcca	taccaaggag	2880

-continued

gggacagtgg	ctggactaat	agaacattat	tctgcaaaaa	cttatggcat	gagttattat	2940
gaatagcett	tattggccca	accttgccgt	tcccagggct	taagtaagtt	tttggttaca	3000
aactgttctt	aaaacgagga	tgtgagacaa	gtggtttcct	gacttggttt	ggtatcaaag	3060
gttctgatct	gagctctgag	tgttctattt	tcctatgttc	ttttggaatt	tatccaaatc	3120
ttatgtaaat	gcttatgtaa	accaagatat	aaaagagtgc	tgattttttg	agtaaaactg	3180
caacagtcc	aacattcacc	tcttgtgtgt	ttgtgtctgt	tcgccatccc	gtctccgctc	3240
gtcacttacc	cttcacttcc	cagaggggtc	ccccgcagac	ccggcgtag	aggatccgca	3300
cccttgatga	ctccgtctga	atttttgggt	tcagtttggg	accgaagctg	cgcgccgctg	3360
ctgcttgta	cttgtttgac	tgttggaatt	gtttgtcttc	tttgtgacct	gactgtgggt	3420
ttctggacgt	gttgtgtctg	ttagtgtctt	tttgactttt	gtttcgtgtt	tgaatttgga	3480
ctgacgactg	tgtttaaaat	cttagaccga	cgactgtgtt	tgaaatcatg	aaactgtttg	3540
ctttgttcgt	cgaagagttt	tacttgggtc	ccttaacgct	tagtgagtaa	gaaacttaat	3600
ttttagtagc	ccgtcttagt	ggcagtggtg	tggttgatag	ccaaagttaa	tttttaaaac	3660
atagtgtttt	gggggttggg	gatttagctc	agtgatagag	ctcttcctta	gcaagcgcaa	3720
ggccctgggt	tcggtcccca	gctctgaaaa	aaaggaaaga	gaaacaaaac	aaaaacatat	3780
agtgttttat	ctgtgcttat	gcccgcagcc	cgagccgcac	ccgcccggga	cggagcccat	3840
gcgcggggcc	agtcggcgcc	cgcccgccgc	cccgccttgc	cccggccccc	gcccccaagc	3900
ttgatataca	attcgcggcc	gcgtcgacct	gcgacggagc	cttgaccgcc	gttgcccggc	3960
cctctccgcg	gcagccccgg	gcttcgcgag	gaatattggg	aaacccatat	ggactacaaa	4020
gaccatgacg	gtgattataa	agatcatgat	atcgattaca	aggatgacga	tgacaagagg	4080
cacaatcaga	tgtgttggtg	gacaccacct	actgtcactg	tttatgtaaa	atcaggggtca	4140
aatagatcac	atcagcctaa	aaagcccat	actctgaagc	gtcctatttg	taaagataat	4200
tggcaagcat	ttgaaaaaaa	tacacataat	aacaacaaat	ctaaacgccc	caaaggacct	4260
tgtctgggtg	tacagcggtc	ggatatgact	gctttcttta	aattatttga	tgacgattta	4320
attcaagatt	tcttgtggat	ggactgctgc	tgtaaaattg	cagacaagta	tcttttgggt	4380
atgacctttg	tttatttcaa	gagggctaaa	tttactataa	gtgagcatat	caggataaat	4440
ttctttattg	ctctgtatct	ggctaataca	gttgaagaag	atgaagaaga	aaccaagtac	4500
gaaatttttc	catgggcttt	agggaaaaa	tgagaaaaat	tgttccctaa	tttcttaaa	4560
ttaagggacc	agctctggga	tagaattgac	tatagggcta	ttgtaagcag	gcgatgttgt	4620
gaggagggtg	tggccattgc	accaacccat	tatatctggc	aaagagaacg	ttctgttcat	4680
cacagtggag	ctgtcagaaa	ctacaacaga	gatgaagttc	agctgccccg	gggacctagt	4740
gccacaccag	tagattgttc	actctgttgt	aaaaaaagaa	gatatgttag	actgggattg	4800
tcttcatcat	catctttatc	cagtcataca	gcaggggtga	cagaaaaaca	ttctcaggac	4860
tcatacaact	cactgtcaat	ggacataata	ggtgatcctt	ctcaagctta	tactggttct	4920
gaaggtatga	tatagtaata	tgcagaatt	cctgcaggtc	gcggcccgca	ctctagagga	4980
tctttgtgaa	ggaaccttac	tcttgttgtg	tgacataatt	ggacaaaacta	cctacagaga	5040
tttaaagctc	taaggtaaat	ataaaatttt	taagtgtata	atgtgttaaa	ctactgattc	5100
taattgtttg	tgtatttttag	attccaacct	atggaactga	tgaatgggag	cagtgggtgga	5160
atgcctttaa	tgaggaaaa	ctgttttgct	cagaagaaat	gccatctagt	gatgatgagg	5220

-continued

ctactgctga ctctcaacat tctactcctc caaaaaagaa gagaaaggta gaagacccca	5280
aggactttcc ttcagaattg ctaagttttt tgagtcatgc tgtgtttagt aatagaactc	5340
ttgcttgctt tgctatttac accacaaagg aaaaagctgc actgctatac aagaaaatta	5400
tggaaaaata tttgatgtat agtgccttga ctagagatca taatcagcca taccacattt	5460
gtagagggtt tacttgcttt aaaaaacctc ccacacctcc ccctgaacct gaaacataaa	5520
atgaatgcaa ttgttgttgt taacttgttt attgcagctt ataatggta caaataaagc	5580
aatagcatca caaatttcac aaataaagca tttttttcac tgcattctag ttgtggtttg	5640
tccaaactca tcaatgtatc ttatcatgtc tggatccact agttctagag cggccgccac	5700
cgcggtggag ctccagcttt tgttccttt agtgagggtt aatttcgagc ttggcgtaat	5760
catggtcata gctgtttcct gtgtgaaatt gttatccgct cacaattcca cacaacatac	5820
gagccggaag cataaagtgt aaagcctggg gtgcctaata agtgagctaa ctcacattaa	5880
ttgcgttgcg ctccactgcc gctttccagt cgggaaacct gtcgtgccag ctgcattaat	5940
gaatcggcca acgcgcgggg agaggcgggt tgcgtattgg gcgctcttc gcttcctcgc	6000
tcactgactc gctgcgctcg gtcgttcggc tgcggcgagc ggatcagct cactcaaagg	6060
cggtaatacg gttatccaca gaatcagggg ataacgcagg aaagaacatg tgagcaaaag	6120
gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc cataggtccc	6180
gccccctga cgagcatcac aaaaatcgac gctcaagta gaggtggcga aacccgacag	6240
gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgctct cctgttcgca	6300
ccctgccgct taccggatac ctgtccgcct ttctcccttc gggaagcgtg gcgctttctc	6360
atagctcacg ctgtaggatc ctacgttcgg ttaggtcgt tcgctccaag ctgggctgtg	6420
tgcacgaacc ccccgttcag ccgcaccgct gcgccttacc cggtaactat cgtcttgagt	6480
ccaaccgggt aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca	6540
gagcgaggta tgtaggcgggt gctacagagt tcttgaagtg gtggcctaac tacggctaca	6600
ctagaaggac agtatattggt atctgcgctc tgcgtgaagc agttaccttc ggaaaaagag	6660
ttggtagctc ttgatccggc aaacaaacca ccgctggtag cgggtggttt ttgtttgca	6720
agcagcagat tacgcgcaga aaaaaaggat tcacaagaaga tcctttgatc ttttctacgg	6780
ggctctgacg tcagtgaac gaaaactcac gttaagggtt tttggctatg agattatcaa	6840
aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaaatca atctaaagta	6900
tatatgagta aacttggtct gacagttacc aatgcttaat cagtgaggca cctatctcag	6960
cgatctgtct atttcgttca tccatagttg cctgactccc cgtcgtgtag ataactacga	7020
tacgggaggg cttaccatct ggccccagtg ctgcaatgat accgcgagac ccacgctcac	7080
cggctccaga tttatcagca ataaccagc cagccggaag ggccgagcgc agaagtggtc	7140
ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccgggaagct agagtaagta	7200
gttcgccagt taatagtttg cgcaacgttg ttgccattgc tacaggcatc gtggtgtcac	7260
gctcgtcgtt tggtatggct tcattcagct ccggttccca acgatcaagg cgagttacat	7320
gatcccccat gttgtgcaaa aaagcgggta gtccttcgg tcctccgacg gttgtcagaa	7380
gtaagtggc cgcagtgtta tcaactcatg ttatggcagc actgcataat tctcttactg	7440
tcatgccatc cgtaaatgct tttctgtgta ctggtagta ctcaaccaag tcattctgag	7500
aatagtgtat gcggcgaccg agttgctctt gcccggcgtc aatacgggat aataccgcgc	7560
cacatagcag aactttaaaa gtgctcatca ttggaaaacg ttcttcgggg cgaaaactct	7620

-continued

```

caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca cccaactgat 7680
cttcagcatc ttttactttc accagcgttt ctgggtgagc aaaaacagga aggcaaatg 7740
ccgcaaaaaa ggggaataagg gcgacacgga aatgttgaat actcatactc ttcctttttc 7800
aatattattg aagcatttat cagggttatt gtctcatgag cggatacata ttggaatgta 7860
tttagaaaaa taaacaaata ggggttcgc gcacatttcc cggaaaagtg c 7911

```

```

<210> SEQ ID NO 6
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward primer (A424)

```

```

<400> SEQUENCE: 6

```

```

gccagaattc gatttatgca tgttgtttac tgagc 35

```

```

<210> SEQ ID NO 7
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse primer (A425)

```

```

<400> SEQUENCE: 7

```

```

gctcagtaaa caacatgcat aaatcgaatt ctggc 35

```

```

<210> SEQ ID NO 8
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward primer (A210)

```

```

<400> SEQUENCE: 8

```

```

cccttgaacc tcctcgttcg acc 23

```

```

<210> SEQ ID NO 9
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse primer (A211)

```

```

<400> SEQUENCE: 9

```

```

gagcctgggg actttccaca ccc 23

```

```

<210> SEQ ID NO 10
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Forward primer F1 (A252)

```

```

<400> SEQUENCE: 10

```

```

gttttatctg tgcttatgcc 20

```

```

<210> SEQ ID NO 11
<211> LENGTH: 19
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Reverse primer F1 (A253)

```

-continued

<400> SEQUENCE: 11

gctcgtatgt tgtgtggaa

19

<210> SEQ ID NO 12

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Forward primer F2 (A254)

<400> SEQUENCE: 12

aaccatcacc ctaatcaagt

20

<210> SEQ ID NO 13

<211> LENGTH: 18

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Reverse primer F2 (A255)

<400> SEQUENCE: 13

gtcgccgcat acactatt

18

<210> SEQ ID NO 14

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Forward primer F3 (A256)

<400> SEQUENCE: 14

ttatccagtc atacagcagg

20

<210> SEQ ID NO 15

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Reverse primer F3 (A257)

<400> SEQUENCE: 15

acccctgctg tatgactgga

20

<210> SEQ ID NO 16

<211> LENGTH: 19

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Forward primer F4 (A258)

<400> SEQUENCE: 16

gaccagaatg tccaccagg

19

<210> SEQ ID NO 17

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Reverse primer F4 (A259)

<400> SEQUENCE: 17

gccacctctg acttgagcgt

20

<210> SEQ ID NO 18

<211> LENGTH: 3891

-continued

<212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Flag-Spyla-pTRE-Tight fusion gene fragment
 construct

<400> SEQUENCE: 18

ctcgagttta ctcctatca gtgatagaga acgtatgtcg agtttactcc ctatcagtga	60
tagagaacga tgtcgagttt actcctatc agtgatagag aacgtatgtc gagtttactc	120
cctatcagtg atagagaacg tatgtcgagt ttactcccta tcagtgatag agaacgtatg	180
tcgagtttat ccctatcagt gatagagaac gtatgtcgag tttactccct atcagtgata	240
gagaacgtat gtcgaggtag gcgtgtacgg tgggaggcct atataagcag agctcgttta	300
gtgaaccgtc agatcgctg gagaattcgc ggccgcgtcg acctgcgacg gagccttgac	360
cgccgttgcc cgccctctc ccgcgcagcc cggggcttcc gcaggaatat tgggaaaccc	420
atatggacta caaagaccat gacggtgatt ataaagatca tgatatcgat tacaaggatg	480
acgatgacaa gaggcacaat cagatgtgtt gtgagacacc acctactgtc actgtttatg	540
taaaatcagg gtcaaataga tcacatcagc ctaaaaagcc cattactctg aagcgctcta	600
tttgtaaaga taattggcaa gcatttgaaa aaaatacaca taataacaac aaatctaaac	660
gccccaaagg accttgtctg gttatacagc gtcaggatat gactgctttc tttaaattat	720
ttgatgacga tttaatcaa gatttcttgt ggatggactg ctgctgtaaa attgcagaca	780
agtatctttt ggctatgacc tttgtttatt tcaagagggc taaatttact ataagtgagc	840
ataccaggat aaatttcttt attgctctgt atctggctaa tacagttgaa gaagatgaag	900
aagaaaccaa gtacgaaatt tttccatggg ctttagggaa aaactggaga aaattgttcc	960
ctaatttctt aaagttaagg gaccagctct gggatagaat tgactatagg gctattgtaa	1020
gcaggcgatg ttgtgaggag gttatggcca ttgcaccaac ccattatatac tggcaaagag	1080
aacgttctgt tcatcacagt ggagctgtca gaaactacaa cagagatgaa gttcagctgc	1140
cccggggacc tagtgccaca ccagtagatt gttcactctg tggtaaaaaa agaagatatg	1200
ttagactggg attgtcttca tcatcatctt tatccagtca tacagcaggg gtgacagaaa	1260
aacattctca ggactcatc aactcactgt caatggacat aataggtgat ccttctcaag	1320
cttatactgg ttctgaaggt atgatatagt aatatgccag aattagattt atgcattgtg	1380
tttactgagc tctagtcagt cctttctggc ggggatacat aataatttat atactccaac	1440
aatatgagtt aaattaatct tgaactttc tccccttca gttactttt gtcttgtgtc	1500
catatttgtt ttgttgtgac ccacctaaac agatttttaa tgtgacctat gttaagttga	1560
aaactaatgc accataagcc tcagtatttt aagagcctga atcatttttt tgaaatgttt	1620
attttattca aaagggtttc aagaagaaaa taaatttact tgtaatctca aaaaaaaaaa	1680
aaaaaaaaa atctagagga tcataatcag ccataaccaca tttgtagagg ttttacttgc	1740
tttaaaaaac ctcccacacc tcccctgaa cctgaaacat aaaatgaatg caattgttgt	1800
tgtaacttg tttattgcag cttataatgg ttacaaataa agcaatagca tcacaaattt	1860
cacaaataa gcattttttt cactgcctcg agcttctctg ctactgact cgctgcgctc	1920
ggtcggtcgg ctgcggcgag cggtatcagc tcaactcaag gcggtaatc gggtatccac	1980
agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa	2040
ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgccccctg acgagcatca	2100
caaaaatcga cgctcaagtc agaggtggcg aaaccgcaga ggactataaa gataccaggc	2160

-continued

```

gtttcccccct ggaagctccc tcgtgcgctc tctgtttccg accctgccgc ttaccggata 2220
cctgtccgcc tttctccctt cgggaagcgt ggcgctttct caatgctcac gctgtaggta 2280
tctcagttcg gtgtaggteg ttcgctccaa gctgggctgt gtgcacgaac ccccggttca 2340
gcccgaaccg tgcgccttat ccggttaacta tcgtcttgag tccaaccggg taagacacga 2400
cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg 2460
tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg 2520
tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 2580
caaaaaaacc accgctggta gcggtgggtt ttttgtttgc aagcagcaga ttacgcgcag 2640
aaaaaaagga tctcaagaag atcctttgat cttttctacg gggctctgacg ctcagtggaa 2700
cgaaaaactc cgttaaggga ttttggtcac gagattatca aaaaggatct tcacctagat 2760
ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 2820
tgacagttac caatgcttaa tcagtgggc acctatctca gcgatctgtc tatttcgttc 2880
atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc 2940
tggcccccagt gctgcaatga taccgcgaga cccacgctca ccgctccag atttatcagc 3000
aataaaaccg ccagccggaa gggccgagcg cagaagtggc cctgcaactt tatccgcctc 3060
catccagtct attaatgtt gccgggaagc tagagtaagt agttcgccag ttaatagttt 3120
gcgcaacggt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc 3180
ttcattcagc tccgggtccc aacgatcaag gcgagttaca tgatccccc tggtgtgcaa 3240
aaaagcgggt agctccttcg gtccctccgac cgttgtcaga agtaagttgg ccgcagtgtt 3300
atcactcatg gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg 3360
cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtga tgcggcgacc 3420
gagttgctct tgcccgcgct caatacggga taataccgcg ccacatagca gaactttaa 3480
agtgtctcat attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt 3540
gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt 3600
caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaa agggaataag 3660
ggcgacacgg aaatgttgaa tactcactact cttccttttt caatattatt gaagcattta 3720
tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat 3780
aggggttccg cgcacatttc cccgaaaagt gccacctgac gtctaagaaa ccattattat 3840
catgacatta acctataaaa ataggcgtat cacgaggccc ttcgctcttc a 3891

```

<210> SEQ ID NO 19

<211> LENGTH: 26

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Primer (A548)

<400> SEQUENCE: 19

atcagtata gagaacgatg tcgagt

26

<210> SEQ ID NO 20
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer (A549)

<400> SEQUENCE: 20

ttgtgcctgt tgcacgtc at

22

We claim:

1. A transgenic non-human animal model comprising germ cells and somatic cells having a Spy1A-pTRE-Tight gene sequence introduced into the genome of said animal model or an ancestor of said animal model at an embryonic stage, wherein the gene sequence comprises a human Spy1A gene.

2. The transgenic non-human animal model of claim 1, wherein said animal model is hemizygous of said Spy1A-pTRE-Tight gene sequence, and said human Spy1A gene comprises a modified humanSpy1A gene of SEQ ID NO: 1 or a conservatively modified variant thereof.

3. The transgenic non-human animal model of claim 1, wherein said Spy1A-pTRE-Tight gene sequence is introduced into the genome of said animal model or said ancestor by microinjecting a fragment sequence obtained from restriction enzyme digestion of SEQ ID NO: 18 or a conservatively modified variant thereof with XhoI and A1wNI.

15 4. The transgenic non-human animal model of claim 3, wherein said animal is selected to express the Spy1A gene and develop cancer when administered with a tetracycline.

5. The transgenic non-human animal model of claim 4, wherein said tetracycline is doxycycline.

20 6. The transgenic non-human animal model of claim 4, wherein said cancer is breast cancer.

7. The transgenic non-human animal model of claim 3, wherein said animal model is selected from the group consisting of a mouse and a rat.

25 8. A method for screening an agent for treating or preventing cancer, the method comprising administering the agent into the animal model of claim 3 and detecting size reduction of a tumor caused by the cancer.

30 9. The method of claim 8, wherein said cancer is breast cancer.

* * * * *